Health Care Equipment

MICROPORT NEURO

MICROPORT NEURO released FY2025 9 Months earnings on March 25, 2026 (BJT), actual revenue HKD 637.38 M, actual EPS HKD 0.2611

MICROPORT NEURO released FY2025 Q3 earnings on March 25, 2026 (BJT), with actual revenue of HKD 222.76 M and EPS of HKD 0.0869

MICROPORT NEURO released FY2025 Q4 earnings on March 25 During-Market (BJT), actual revenue HKD 0, actual EPS HKD 0

MICROPORT NEURO released FY2025 earnings on March 25 During-Market (BJT), actual revenue HKD 863.97 M (forecast HKD 922.99 M), actual EPS HKD 0.3497 (forecast HKD 0.5115)

MicroPort NeuroTech's APOLLO Dream® stent system receives FDA Breakthrough Device designation

MICROPORT NEURO to Release FY2025 Earnings on March 25 During-Market (BJT), Forecast Revenue HKD 907.45 M, EPS HKD 0.5029

MicroPort Scientific Corporation reduced holdings in MicroPort NeuroTech

MicroPort Scientific Corporation reduced holdings of MicroPort NeuroTech by 56 million shares

MICROPORT NEURO released FY2025 Q1 earnings on August 27 (BJT), actual revenue HKD 205.05 M, actual EPS HKD 0.0861

MicroPort NeuroTech Announces 2025 H1 Results: Revenue and Profit Decline but International Business Shows Strong Growth

MICROPORT NEURO released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue HKD 209.56 M, actual EPS HKD 0.088

MICROPORT NEURO released FY2025 Semi-Annual earnings on August 27 After-Market (BJT), actual revenue HKD 414.61 M, actual EPS HKD 0.1741

MicroPort NeuroTech Issues 424,800 Scrip Dividend Shares

MICROPORT NEURO to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

We&amp;#39;Tron Capital Limited reduced its holdings of MicroPort NeuroTech by 5.009 million shares

NMPA Policy Support Boosts Brain-Computer Interface Stocks

Neuralink Makes New Progress in Brain-Computer Interface Technology

Microvention Brain Science Signs Three-Year Master Distribution Agreement with Microvention

Microport Neurosciences Announces Director Changes at Annual General Meeting

Hong Kong-listed brain-machine interface 概念股 decline

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02160

688351

00853

02172

02252

159883

562600

159898

688016

Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a "Buy" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its "GloMatrix" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points

AASTOCKS

MP CARDIOFLOW-B

MICROPORT EP

MICROPORT

MircroPort Medbot-B

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Endovastec

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

CICC analyst maintained a Buy rating on MicroPort NeuroTech Limited yesterday and set a price target of HK$12.50.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on MicroPort NeuroTech Limited is a Moderate Buy with an average price target of HK$12.50.

Tip Ranks

CICC Reaffirms Their Buy Rating on MicroPort NeuroTech Limited (2172)

MicroPort announced its 2025 annual performance, with revenue of USD 1.105 billion, an increase of 7.2% year-on-year; gross profit of USD 635 million, an increase of 10.5%. It recorded a net profit of USD 48.52 million, compared to a loss of USD 214 million in the previous year, turning a loss into a profit; earnings per share of 2.59 cents. No final dividend will be distributed

"Performance" MICROPORT achieved a net profit of USD 48.52 million for the entire year, turning a loss into a profit

MICROPORT NEU announced its 2025 annual performance, with revenue of 790 million RMB, an annual increase of 3.8%. It recorded a net profit of 185 million RMB, a decline of 27.4%, with earnings per share of 32 cents. A final dividend of 9 Hong Kong cents was declared

In the performance report, MICROPORT NEU's annual net profit is 185 million RMB, a decrease of 27.4%, with a final dividend of 7 Hong Kong cents

MicroPort NeuroScientific grows revenue on overseas strength despite profit hit

MicroPort NeuroScientific grows revenue on overseas strength despite profit hit

MicroPort CardioFlow Medtech Corp. has announced a change in its reporting currency from Renminbi to U.S. dollars to align with its globalization strategy and the contribution of its subsidiary, MicroPort Cardiac Rhythm Management Limited. This change aims to provide clearer financial performance insights for shareholders and investors, with prior-year figures restated in USD starting with the 2025 annual report. The current analyst rating for the stock (HK:2160) is a Hold, with a price target of HK$0.76.

MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars

Shares of MicroPort Endovascular MedTech Group surged 10.2% to CNY111.80 after the US FDA granted Breakthrough Device Designation to its innovative stent graft system, expediting market approval. The Hector Multi-Branch Thoracic Aortic Stent Graft System aims for minimally invasive treatment of thoracic aortic lesions. MicroPort reported a 12% rise in net profit to CNY563 million last year, driven by innovative product launches and a 55% increase in overseas sales. The device has received EU certification and is in clinical trials in China, addressing high-risk aortic arch lesions with less invasive methods.

Yicai

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

China's brain-computer interface (BCI) industry is rapidly advancing, transitioning from research to commercialization with strong policy support and growing investor interest. Startups like NeuroXess and Gestala are leading the charge, backed by a national roadmap targeting major milestones by 2027. Key factors driving this growth include robust clinical resources, mature manufacturing capabilities, and strategic investments. The BCI market in China is projected to exceed $530 million by 2025, with long-term estimates reaching over 120 billion yuan by 2040, positioning Chinese firms to compete with U.S. leaders like Neuralink.

TechCrunch

China’s brain-computer interface industry is racing ahead

MICROPORT NEURO(02172.HK)

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

CICC Reaffirms Their Buy Rating on MicroPort NeuroTech Limited (2172)

"Performance" MICROPORT achieved a net profit of USD 48.52 million for the entire year, turning a loss into a profit

In the performance report, MICROPORT NEU's annual net profit is 185 million RMB, a decrease of 27.4%, with a final dividend of 7 Hong Kong cents

MicroPort NeuroScientific grows revenue on overseas strength despite profit hit

MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

China’s brain-computer interface industry is racing ahead